Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoirData on the ...
Schematic representation of histone-modifying factor recruitment on cccDNA minichromosomes in relation to viral protein HBx. In the presence of HBx, histone-modifying factors such as p300/CBP, Set1A, ...
Precision BioSciences, Inc. DTIL stock is up during Wednesday’s premarket session, trading higher by 10.55% as the company is ...
Technique measuring the cccDNA marker may allow earlier detection of hepatocellular carcinoma in patients, reports The Journal of Molecular Diagnostics Philadelphia, April 12, 2018 - Chronic hepatitis ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Paul Martin, MD, FACP, Professor of Medicine and Chief, Division of Hepatology, Center for Liver Disease, University of Miami School of Medicine, Miami, Florida There are no human data correlating ...
Developing new, more sensitive assays to detect chronic infections, like those from the hepatitis B virus (HBV), is imperative to when trying to manage associated diseases such as cirrhosis and ...
Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma. Despite widespread vaccination and antiviral treatments, millions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results